Panelists discuss managing infusion-related reactions with amivantamab and lazertinib, compare these reactions with those from other treatments, and review SKIPPirr data to provide insights on incorporating prophylactic dexamethasone 8 mg, addressing implementation barriers, and educating patients.
EP. 1: The Role of Amivantamab Plus Lazertinib for NSCLC
October 1st 2024Panelists discuss how amivantamab, FDA approved for first-line treatment of advanced non–small cell lung cancer with specific EGFR mutations, can lead to significant infusion-related reactions, including serious cases that may require dose adjustments or discontinuation.
2 Commerce Drive
Cranbury, NJ 08512